Jesse
Senior Member (Voting Rights)
Yes, exactly. It's probably a little bit of both though. If we had more leads there might also have been more interest in off-patent drugs.Researcher Jeroen den Dunnen wanted to do a daratumumab trial and I believe a sonlicromanol trial, but he wasn't able to due to the current constraints of only trying drugs that weren't patented. In Long-Covid ZonMw allowed it though.
Promising medicines for ME/CFS: call for drug repurposing | Jeroen den Dunnen | 60 comments
With considerable disappointment, our team has decided not to submit a proposal for a clinical trial in ME/CFS in the upcoming ZonMw call. I would like to briefly explain why. For those who may not be familiar with the background: after many years of advocacy by ME/CFS patients and patient...www.linkedin.com